Turnover€166k
EBIT margin5.2%
Net result€1k
Working capital€-31k+30.7%
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of Oncolo-Co is 0.4% (very low). The 2024 annual accounts show negative equity (€-4k) and a net result of €1k. Equity is shrinking by ~198.6% per year across the filed fiscal years. Its solvency ranks better than 5% of 1234 sector peers (fiscal year 2024). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 3 annual accounts.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone0.4%
Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector
−Young company
+Higher-failure-rate region
+
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
Financials
FY 2024
€-4k
equity
Turnover—
Net result€1kHealth16/100 · Critical
See full annual accounts
People & board
No director data processed yet.
To directors Publicationslatest 18-02-2026
5
publications in the State GazetteRegistered office moved from Antwerpen to VorstAll publications & acts Network & structure
2
connected companiesSee network & structure
Connections
2 connected companiesTrust signals
3 signalsMore than 3 years active
Founded in 2022 — past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags
0 events
No administrative flags
Company registry (CBE)
Crossroads BankActivities
Praktijken van specialisten86220Activiteiten van medisch specialisten86220
Primary activity highlighted.
Names & trade names
| Legal nameNL | Oncolo-Co |
Registered office
Besmelaan 103
1190 Vorst, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.